Literature DB >> 28345314

Prevalence and Clinical Characteristics of Dyslipidemia in Koreans.

Jee Sun Jeong1, Hyuk Sang Kwon2.   

Abstract

The prevalence of hypercholesterolemia in Koreans 30 years old and over was 19.5% in 2015 according to the Korean Nutrition and Health Examination Survey, which means that one-fifth of adults had hypercholesterolemia. The prevalence of hypertriglyceridemia in adults 30 years of age and older was 16.8% in 2015, and men had a 2-fold higher prevalence of hypertriglyceridemia than women (23.9% vs. 10.4%). The awareness of hypercholesterolemia in Koreans was higher in women than among men (62.4% vs. 51.4%). It increased with age; the level of awareness in participants 30 to 49 years of age (32.1% in men and 32.6% in women) was less than half of that observed among respondents ≥65 years old (77.5% in men and 78.0% in women). Regular check-ups for dyslipidemia and the active management thereof are urgent in Korean men aged 30 to 49. In women, the perimenopausal period is crucial for the prevention and management of metabolic syndrome, including dyslipidemia. Overall, improvements in awareness and treatment in the age group of 30 to 49 years in both men and women remain necessary.
Copyright © 2017 Korean Endocrine Society.

Entities:  

Keywords:  Dyslipidemias; Hypercholesterolemia; Hypertriglyceridemia; Metabolic syndrome

Year:  2017        PMID: 28345314      PMCID: PMC5368118          DOI: 10.3803/EnM.2017.32.1.30

Source DB:  PubMed          Journal:  Endocrinol Metab (Seoul)        ISSN: 2093-596X


INTRODUCTION

Dyslipidemia is a leading cause of cardiovascular disease and mortality worldwide [12]. According to data from Statistics Korea [3], the leading cause of death was cancer in 2015, with the second and third ranks occupied by heart disease and cerebrovascular disease, respectively. Diabetes was the sixth most common cause of death. Atherosclerosis is a preceding pathologic condition in the development of both heart and cerebrovascular diseases [45], and dyslipidemia is the greatest risk factor for atherosclerosis. Therefore, there is no doubt that dyslipidemia is a major risk factor for cardiovascular disease and mortality in Koreans. This review article will discuss the epidemiologic characteristics of dyslipidemia in Korean adults. The statistics regarding the prevalence of dyslipidemia in Korean adults in this article were obtained from the Korean Nutrition and Health Examination Survey (KNHANES) conducted from 2010 to 2015 [6].

PREVALENCE OF HYPERCHOLESTEROLEMIA IN KOREANS

The prevalence of hypercholesterolemia in Koreans 30 years old and over was 19.5% in 2015 (Table 1). Hypercholesterolemia was defined as a serum total cholesterol level ≥240 mg/dL or the use of lipid-lowering medications. The estimated population with hypercholesterolemia was approximately 6.6 million. The prevalence of hypercholesterolemia increased in an age-dependent manner; in particular, it increased approximately 3-fold in women in their 50s and older. Trends in the prevalence of hypercholesterolemia over the last 5 years are shown in Table 2. It increased from 13.5% in 2010 to 17.9% in 2015. Moreover, it increased from 8.0% in 2005 to 13.5% in 2010; it then remained steady for the following 5 years, but increased by 3.3% points in 2015.
Table 1

Prevalence of Hypercholesterolemia among Korean Adults ≥30 Years Old in 2015

Age, yrPrevalence of hypercholesterolemia, %a
TotalMaleFemale
≥30b19.516.922.1
30–4912.114.79.4
50–6424.518.130.9
≥6530.320.837.6

aSerum total cholesterol ≥240 mg/dL or taking lipid-lowering medications; bAll over 30 years old.

Table 2

Trends in the Prevalence of Hypercholesterolemia, 2010 to 2015

VariableHypertriglyceridemia, %a
201020112012201320142015
Total13.5±0.613.8±0.514.5±0.614.9±0.614.6±0.717.9±0.7
Male13.0±0.912.6±0.912.2±0.813.6±0.813.9±1.016.5±1.0
Female13.4±0.714.9±0.716.4±0.915.9±0.815.0±0.819.1±0.8

Values are expressed as mean±standard error.

aSerum total cholesterol ≥240 mg/dL or taking lipid-lowering medications.

According to data from the National Health and Nutrition Examination Surveys (NHANES) in the United States [7], the prevalence of hypercholesterolemia in adults aged 20 and over increased from 22.8% in the 1988 to 1994 surveys to 27.8% in the 2011 to 2014 surveys (Table 3). Considering the difference in the age of the population between the KNHANES (30 and over) and NHANES (20 and over), its prevalence in the United States is quite high. However, the percent of the population with high cholesterol declined from 20.8% in the 1988 to 1994 surveys to 11.9% in the 2011 to 2014 surveys. The mean serum total cholesterol level also declined during the same period in the United States. This means that the increasing pattern of hypercholesterolemia in United States is mainly due to an increasing percentage of the population taking lipid-lowering medications [8]. This corresponds to a decreasing pattern of cardiovascular diseases such as coronary heart disease [910]. In contrast, the mean serum total cholesterol level did not decline in Korea during roughly the same period (from 183.9±0.64 mg/dL in 1998 to 185.1±0.64 mg/dL in 2010) [11], even though the percentage of the population taking lipid-lowering medications increased over the past 10 years in Korea (from 2.8% in 2003 to 12.9% in 2013) [12].
Table 3

Cholesterol Levels among Adults Aged 20 and over in the United States Based on the National Health and Nutrition Examination Survey for Selected Years (1988 to 1994 through 2011 to 2014)

20 Years and over, age-adjusted1988–19941999–20022003–20062007–20102011–2014
Population with hypercholesterolemia, %a
 Both sexes22.825.027.727.427.8
 Male21.125.327.728.028.4
 Female24.024.327.426.727.3
Population with high cholesterol, %b
 Both sexes20.817.316.313.711.9
 Male19.016.415.112.610.8
 Female22.017.817.114.412.7
Mean serum total cholesterol level, mg/dL
 Both sexes206203200196192
 Male204202198194189
 Female207204202198195

aSerum total cholesterol ≥240 mg/dL or taking cholesterol-lowering medications; bSerum total cholesterol ≥240 mg/dL.

PREVALENCE OF HYPERTRIGLYCERIDEMIA IN KOREANS

The prevalence of hypertriglyceridemia in adults aged 30 and over was 16.8% in 2015, and the estimated population with hypertriglyceridemia was approximately 5.8 million (Table 4). Men had a 2-fold higher prevalence of hypertriglyceridemia than was observed in women (23.9% vs. 10.4%). Among participants under 50 years of age, this difference was much larger, with a 3-fold higher prevalence in men (27.5% vs. 7.9%). This means that one out of every three or four Korean men aged 30 to 49 has hypertriglyceridemia.
Table 4

Prevalence of Hypertriglyceridemia in Korean Adults ≥30 Years Old in 2015

Age, yrPrevalence of hypertriglyceridemia, %a
TotalMaleFemale
≥30b16.823.910.4
30–4917.327.57.9
50–6417.924.112.2
≥6513.914.913.0

aSerum triglyceride level ≥200 mg/dL; bAll over 30 years old.

Although little change was observed in the prevalence of hypertriglyceridemia in the most recent 5 years (from 16.6 % in 2010 to 16.8% in 2015), a large increase has taken place over the last 20 years, since the prevalence of hypertriglyceridemia in 1998 was only 10.2%, and a much lower level was also observed in men (14.9%) (Table 5).
Table 5

Trends in the Prevalence of Hypertriglyceridemia, 2010 to 2015

VariableHypertriglyceridemia, %a
201020112012201320142015
Total16.6±0.716.2±0.716.8±0.817.1±0.717.9±0.816.8±0.8
Male23.9±1.323.9±1.221.1±1.323.8±1.326.8±1.324.6±1.5
Female9.7±0.78.9±0.712.5±0.910.9±0.79.8±0.89.7±0.8

Values are expressed as mean±standard error.

aSerum triglyceride level ≥200 mg/dL.

Similar trends regarding sex and age differences in hypertriglyceridemia can be seen in the NHANES [13]. Even though the definition for hypertriglyceridemia is different in the NHANES, where it is defined as a triglyceride level of 150 mg/dL or more, approximately one-fourth of adults aged 20 and over had hypertriglyceridemia in the 2009 to 2012 surveys. A sex difference was seen in adults aged 20 to 39 (25.1% in men vs. 14.7% in women) and 40 to 59 (34.9% in men vs. 23.0% women), but not in adults aged 60 and over. However, the prevalence of hypertriglyceridemia declined from 33.3% in the 2001 to 2004 surveys to 25.1% in the 2009 to 2012 surveys. This declining pattern was seen in both sexes and all age groups, unlike what was observed in Koreans [11]. Although low density lipoprotein cholesterol is the primary target for lipid control in the prevention of cardiovascular diseases, high triglycerides combined with low levels of high density lipoprotein cholesterol is a typical profile of atherogenic dyslipidemia [1415]. High triglycerides in males may occur due to alcohol consumption and unhealthy lifestyles in those age groups. For example, high-risk alcohol consumption, defined as an average consumption of ≥7 drinks in men (≥5 drinks in women) on ≥2 occasions per week was most common in males 30 to 49 years of age, and was 4- to 5-fold more common than in women of the same age group. Furthermore, the proportion of high-fat diets was approximately twice as high among men as among women in respondents 30 to 49 years of age (15.7% vs. 8.9%). Therefore, active screening for hypertriglyceridemia and managing hypertriglyceridemia through lifestyle modifications, including reductions in alcohol consumption, are urgent and necessary for Korean men, especially those aged 30 to 49.

MANAGEMENT OF HYPERCHOLESTEROLEMIA IN KOREANS

Awareness of hypercholesterolemia in Koreans was found to be greater among women than among men (62.4% vs. 51.4%) (Table 6). It increased with age; the level of awareness in participants 30 to 49 years of age (32.1% in men and 32.6% in women) was less than half of that observed among respondents >65 years old (77.5% in men and 78.0% in women). Furthermore, the rate of treatment, which was defined as the proportion of the population taking a lipid-lowering medication ≥20 days a month, was only 45.5% in the population with hypercholesterolemia. Due to this unacceptably low rate of treatment, the rate of control in those with hypercholesterolemia, which was defined as the proportion of the population with hypercholesterolemia with a serum total cholesterol level <200 mg/dL, was also low, at 39.7%. However, the rate of control in the population treated with lipid-lowering medications was 84.3%, which means that when it is appropriately diagnosed and treated, hypercholesterolemia is easy to control.
Table 6

Management Status of Hypercholesterolemia in Participants of the Sixth Korean National Health and Nutrition Examination Survey (2013 to 2015)

Age, yrTotalMaleFemale
Awarenessa
 ≥30b57.751.462.4
 30–4932.332.132.6
 50–6462.961.763.6
 ≥6577.977.578.0
Treatmentc
 ≥30b45.539.849.9
 30–4919.318.620.5
 50–6448.750.447.7
 ≥6569.969.969.9
Rate of control (in those with hypercholesterolemia)d
 ≥30b39.737.141.7
 30–4915.815.815.8
 50–6442.847.440.0
 ≥6561.668.459.0
Rate of control (in the treated)e
 ≥30b84.388.481.8
 30–4976.576.377.0
 50–6484.990.281.5
 ≥6585.993.682.9

Values are expressed as percentage.

aAwareness: proportion of the population diagnosed by a doctor; bAll over 30 years old; cTreatment: proportion of the population taking a lipid-lowering medication ≥20 days a month; dRate of control (in those with hypercholesterolemia): proportion of the population with hypercholesterolemia with a serum total cholesterol level <200 mg/dL; eRate of control (in the treated): proportion of the population with a serum total cholesterol level <200 mg/dL among those treated with lipid-lowering medications.

Table 7 shows the management status of hypercholesterolemia during the most recent 10 years; the awareness rate in 2005 was only 24.0%, and the treatment rate was 17.3%. Since then, through the fourth to sixth stages of the KNHANES, the rate of awareness and treatment has increased by 10% points at every stage. Thus, all parameters regarding management have improved by 20% to 30% points compared with those of the third KNHANES conducted in 2005.
Table 7

Management Status of Hypercholesterolemia during the Most Recent 10 Years

Variable2005 (third KNHANES)2007–2009 (fourth KNHANES)2010–2012 (fifth KNHANES)2013–2015 (sixth KNHANES)
Awarenessa
 Total24.0±2.438.8±1.547.4±1.457.7±1.3
 Male24.4±4.237.0±2.245.2±2.351.4±2.0
 Female23.8±3.040.3±1.849.1±1.762.4±1.6
Treatmentb
 Total17.3±2.126.9±1.337.3±1.445.5±1.3
 Male17.5±3.624.6±1.935.8±2.039.8±2.0
 Female17.1±2.628.6±1.638.4±1.849.9±1.6
Rate of control (in those with hypercholesterolemia)c
 Total10.8±1.720.3±1.129.9±1.239.7±1.2
 Male11.0±2.520.2±1.728.7±1.837.1±1.9
 Female10.6±2.220.3±1.430.9±1.641.7±1.5
Rate of control (in the treated)d
 Total62.3±6.673.5±2.278.8±1.684.3±1.2
 Male63.1±11.080.6±3.379.3±2.888.4±1.8
 Female61.8±7.968.8±2.978.5±1.981.8±1.6

Values are expressed as mean±standard error.

KNHANES, Korean National Health and Nutrition Examination Survey.

aAwareness: proportion of the population diagnosed by a doctor; bTreatment: proportion of the population taking a lipid-lowering medication ≥20 days a month; cRate of control (in those with hypercholesterolemia): proportion of the population with hypercholesterolemia with a serum total cholesterol level <200 mg/dL; dRate of control (in the treated): proportion of the population with a serum total cholesterol level <200 mg/dL among those treated with lipid-lowering medications.

A recent study reported 30-year trends in mortality from cardiovascular diseases in Korea [16]. The total cardiovascular disease mortality rate declined over the 30-year period from 1983 to 2012, but the mortality rate due to ischemic heart disease continuously increased. As discussed above, the prevalence of hypercholesterolemia has increased in both the United States and Korea, but with different underlying patterns. Therefore, to reduce the burden of cardiovascular disease in Korea, increasing the rate of treatment among those with hypercholesterolemia is essential.

CONCLUSIONS

The prevalence of hypercholesterolemia in Koreans 30 years old and over was 19.5% in 2015, meaning that one-fifth of adults had hypercholesterolemia. Although the management of hypercholesterolemia has improved over the most recent 10 years, this improvement has not proven sufficient to reduce the burden of cardiovascular disease, so it remains necessary to improve awareness and treatment among adults aged 30 to 49. For hypertriglyceridemia, regular check-ups and active management are urgent in Korean men aged 30 to 49. For women, active screening in the perimenopausal period with the goal of preventing hypercholesterolemia and metabolic syndrome is very important.
  12 in total

Review 1.  Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association.

Authors:  Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner
Journal:  Circulation       Date:  2017-01-25       Impact factor: 29.690

2.  Trends in elevated triglyceride in adults: United States, 2001-2012.

Authors:  Margaret Carroll; Brian Kit; David Lacher
Journal:  NCHS Data Brief       Date:  2015-05

3.  Recent Trends in Cardiovascular Mortality in the United States and Public Health Goals.

Authors:  Stephen Sidney; Charles P Quesenberry; Marc G Jaffe; Michael Sorel; Mai N Nguyen-Huynh; Lawrence H Kushi; Alan S Go; Jamal S Rana
Journal:  JAMA Cardiol       Date:  2016-08-01       Impact factor: 14.676

Review 4.  Diabetes, hyperlipidemia, and coronary artery disease.

Authors:  S M Haffner
Journal:  Am J Cardiol       Date:  1999-05-13       Impact factor: 2.778

5.  HDL cholesterol and stroke risk: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Samantha A Reina; Maria M Llabre; Matthew A Allison; John T Wilkins; Armando J Mendez; Martinson K Arnan; Neil Schneiderman; Ralph L Sacco; Mercedes Carnethon; J A Chris Delaney
Journal:  Atherosclerosis       Date:  2015-09-28       Impact factor: 5.162

6.  Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012.

Authors:  Qiuping Gu; Ryne Paulose-Ram; Vicki L Burt; Brian K Kit
Journal:  NCHS Data Brief       Date:  2014-12

7.  Hypertriglyceridemia as a cardiovascular risk factor.

Authors:  M A Austin; J E Hokanson; K L Edwards
Journal:  Am J Cardiol       Date:  1998-02-26       Impact factor: 2.778

Review 8.  Inflammation in atherosclerosis.

Authors:  Peter Libby
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

9.  Prevalence and Management of Dyslipidemia in Korea: Korea National Health and Nutrition Examination Survey during 1998 to 2010.

Authors:  Eun Roh; Seung-Hyun Ko; Hyuk-Sang Kwon; Nan Hee Kim; Jae Hyeon Kim; Chul Sik Kim; Kee-Ho Song; Jong Chul Won; Dae Jung Kim; Sung Hee Choi; Soo Lim; Bong-Yun Cha
Journal:  Diabetes Metab J       Date:  2013-12-12       Impact factor: 5.376

10.  Thirty-Year Trends in Mortality from Cerebrovascular Diseases in Korea.

Authors:  Seung Won Lee; Hyeon Chang Kim; Hye Sun Lee; Il Suh
Journal:  Korean Circ J       Date:  2016-07-21       Impact factor: 3.243

View more
  8 in total

1.  Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study.

Authors:  Nam Hoon Kim; Ki Hoon Han; Jimi Choi; Juneyoung Lee; Sin Gon Kim
Journal:  BMJ       Date:  2019-09-27

2.  Pre-existing Depression among Newly Diagnosed Dyslipidemia Patients and Cardiovascular Disease Risk.

Authors:  Jihoon Andrew Kim; Seulggie Choi; Daein Choi; Sang Min Park
Journal:  Diabetes Metab J       Date:  2019-11-01       Impact factor: 5.376

3.  The risk of herpes zoster virus infection in patients with depression: A longitudinal follow-up study using a national sample cohort.

Authors:  Hyo Geun Choi; Eui-Joong Kim; Young Kyung Lee; Miyoung Kim
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.889

4.  Effect of Smartphone-Based Lifestyle Coaching App on Community-Dwelling Population With Moderate Metabolic Abnormalities: Randomized Controlled Trial.

Authors:  So Mi Jemma Cho; Jung Hyun Lee; Jee-Seon Shim; Hyungseon Yeom; Su Jin Lee; Yong Woo Jeon; Hyeon Chang Kim
Journal:  J Med Internet Res       Date:  2020-10-09       Impact factor: 5.428

5.  The prevalence of hypercholesterolemia and associated risk factors in Al-Kharj population, Saudi Arabia: a cross-sectional survey.

Authors:  Jamaan Al-Zahrani; Mamdouh M Shubair; Sameer Al-Ghamdi; Abdullah A Alrasheed; Abdulrahman A Alduraywish; Fayez Saud Alreshidi; Saeed Mastour Alshahrani; Majid Alsalamah; Badr F Al-Khateeb; Aljawharah Ibraheem Ashathri; Ashraf El-Metwally; Khaled K Aldossari
Journal:  BMC Cardiovasc Disord       Date:  2021-01-07       Impact factor: 2.298

6.  Prevalence, awareness, treatment, and control of dyslipidemia among diabetes mellitus patients and predictors of optimal dyslipidemia control: results from the Korea National Health and Nutrition Examination Survey.

Authors:  Seung Jae Kim; Oh Deog Kwon; Kyung-Soo Kim
Journal:  Lipids Health Dis       Date:  2021-03-26       Impact factor: 4.315

7.  Effect of Change in Total Cholesterol Levels on Cardiovascular Disease Among Young Adults.

Authors:  Su-Min Jeong; Seulggie Choi; Kyuwoong Kim; Sung Min Kim; Gyeongsil Lee; Seong Yong Park; Yeon-Yong Kim; Joung Sik Son; Jae-Moon Yun; Sang Min Park
Journal:  J Am Heart Assoc       Date:  2018-06-13       Impact factor: 5.501

8.  Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study.

Authors:  Chang-Wook Nam; Dong-Soo Kim; Jianyong Li; Marie T Baccara-Dinet; Ivy Li; Ji-Hyun Kim; Chong-Jin Kim
Journal:  Korean J Intern Med       Date:  2018-09-01       Impact factor: 2.884

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.